Tags

Type your tag names separated by a space and hit enter

The Comprehensive Analysis of Efficacy and Safety of CalliSpheres® Drug-Eluting Beads Transarterial Chemoembolization in 367 Liver Cancer Patients: A Multiple-Center, Cohort Study.
Oncol Res. 2020 May 29; 28(3):249-271.OR

Abstract

This study aimed to investigate the efficacy, safety, and prognostic factors of drug-eluting beads transarterial chemoembolization (DEB-TACE) in treating Chinese patients with liver cancer. A total of 367 liver cancer patients from 24 medical centers were consecutively enrolled in this multiple-center, prospective cohort study, including 275 hepatocellular carcinoma (HCC) cases, 37 intrahepatic cholangiocarcinoma (ICC) cases, and 55 secondary liver cancer cases. All the patients received CalliSpheres® DEB-TACE treatment. Treatment response, overall survival (OS), change of liver function, and adverse events (AEs) were assessed. DEB-TACE treatment achieved 19.9% complete response (CR) and 79.6% objective response rate (ORR), with mean OS of 384 days [95% confidence interval (CI): 375-393 days]. CR and ORR were both higher in HCC patients compared with primary ICC patients and secondary liver cancer patients, while no difference was discovered in OS. Portal vein invasion was an independent risk factor for CR, while portal vein invasion, previous conventional TACE (cTACE) treatment, and abnormal blood creatinine (BCr) were independent risk factors for ORR. In addition, largest nodule size ≥5.0 cm, abnormal albumin (ALB), and abnormal total bilirubin (TBIL) independently correlated with unfavorable OS. Most liver function indexes were recovered to baseline levels at 1-3 months after DEB-TACE. Common AEs were pain, fever, vomiting, and nausea; most of them were at mild grade. CalliSpheres® DEB-TACE is efficient and well tolerated in Chinese liver cancer patients. Portal vein invasion, previous cTACE treatment, largest nodule size, abnormal BCr, ALB, and TBIL correlate with worse prognosis independently.

Authors+Show Affiliations

Department of Radiology, The First Affiliated Hospital, College of Medicine, Zhejiang UniversityHangzhouChina.Department of Radiology, Shulan (Hangzhou) Hospital, Zhejiang University International HospitalHangzhouChina.Department of Radiology, Xixi Hospital of Hangzhou, Hangzhou 6th People's HospitalHangzhouChina.Department of Liver Oncology, Ningbo No. 2 HospitalNingboChina.Department of Radiology, The First Affiliated Hospital, College of Medicine, Zhejiang UniversityHangzhouChina.Hepatobiliary and Pancreatic Interventional Treatment Center, Division of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, College of Medicine, Zhejiang UniversityHangzhouChina.Hepatobiliary and Pancreatic Interventional Treatment Center, Division of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, College of Medicine, Zhejiang UniversityHangzhouChina.Department of Radiology, Hangzhou Cancer HospitalHangzhouChina.Department of Radiology, The First Affiliated Hospital, College of Medicine, Zhejiang UniversityHangzhouChina.Department of Radiology, Taizhou Hospital of Zhejiang ProvinceLinhaiChina.Department of Vascular and Interventional Radiology, The Affiliated Hospital of Medical College of Ningbo UniversityNingboChina.Department of Radiology, Beilun District People's Hospital of NingboNingboChina.Department of Liver Oncology, Ningbo No. 2 HospitalNingboChina.Department of Intervention, The First Affiliated Hospital of Wenzhou Medical UniversityWenzhouChina.Department of Radiology, Lishui Central Hospital, Lishui Hospital of Zhejiang University, The Fifth Affiliated Hospital of Wenzhou Medical UniversityLishuiChina.Department of Intervention, Dongyang People's HospitalDongyangChina.Department of Intervention, The Third Affiliated Hospital of Wenzhou Medical UniversityRuianChina.Department of Intervention, Jinhua Central HospitalJinhuaChina.Department of Hepatobiliary Surgery, Quzhou People's HospitalQuzhouChina.Department of Intervention, Jiaxing First HospitalJiaxingChina.Department of Intervention, Jiaxing Second HospitalJiaxingChina.Interventional Center, Xinchang People's HospitalShaoxingChina.Department of Radiology, The First Affiliated Hospital of Zhejiang Chinese Medical UniversityHangzhouChina.Division of Digestive Endoscopy, Yueqing City People's HospitalYueqingChina.Department of Radiology, Sir Run Run Shaw Hospital, Zhejiang University College of MedicineHangzhouChina.Department of Intervention, Zhejiang Provincial People's HospitalHangzhouChina.Department of Hepatobiliary Surgery, Ningbo Medical Center, Lihuili Eastern HospitalNingboChina.Department of Radiology, Sir Run Run Shaw Hospital, Zhejiang University College of MedicineHangzhouChina.Department of Intervention, Zhejiang Cancer HospitalHangzhouChina.Department of Intervention, Zhejiang Cancer HospitalHangzhouChina.Department of Intervention, Zhejiang Cancer HospitalHangzhouChina.Department of Intervention, Zhejiang Provincial People's HospitalHangzhouChina.Department of Intervention, Zhejiang Cancer HospitalHangzhouChina.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

31856933

Citation

Peng, Zhiyi, et al. "The Comprehensive Analysis of Efficacy and Safety of CalliSpheres® Drug-Eluting Beads Transarterial Chemoembolization in 367 Liver Cancer Patients: a Multiple-Center, Cohort Study." Oncology Research, vol. 28, no. 3, 2020, pp. 249-271.
Peng Z, Cao G, Hou Q, et al. The Comprehensive Analysis of Efficacy and Safety of CalliSpheres® Drug-Eluting Beads Transarterial Chemoembolization in 367 Liver Cancer Patients: A Multiple-Center, Cohort Study. Oncol Res. 2020;28(3):249-271.
Peng, Z., Cao, G., Hou, Q., Li, L., Ying, S., Sun, J., Zhou, G., Zhou, J., Zhang, X., Ji, W., Yu, Z., Li, T., Zhu, D., Hu, W., Ji, J., Du, H., Shi, C., Guo, X., Fang, J., ... Shao, G. (2020). The Comprehensive Analysis of Efficacy and Safety of CalliSpheres® Drug-Eluting Beads Transarterial Chemoembolization in 367 Liver Cancer Patients: A Multiple-Center, Cohort Study. Oncology Research, 28(3), 249-271. https://doi.org/10.3727/096504019X15766663541105
Peng Z, et al. The Comprehensive Analysis of Efficacy and Safety of CalliSpheres® Drug-Eluting Beads Transarterial Chemoembolization in 367 Liver Cancer Patients: a Multiple-Center, Cohort Study. Oncol Res. 2020 May 29;28(3):249-271. PubMed PMID: 31856933.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The Comprehensive Analysis of Efficacy and Safety of CalliSpheres® Drug-Eluting Beads Transarterial Chemoembolization in 367 Liver Cancer Patients: A Multiple-Center, Cohort Study. AU - Peng,Zhiyi, AU - Cao,Guohong, AU - Hou,Qinming, AU - Li,Ling, AU - Ying,Shihong, AU - Sun,Junhui, AU - Zhou,Guanhui, AU - Zhou,Jian, AU - Zhang,Xin, AU - Ji,Wenbin, AU - Yu,Zhihai, AU - Li,Tiefeng, AU - Zhu,Dedong, AU - Hu,Wenhao, AU - Ji,Jiansong, AU - Du,Haijun, AU - Shi,Changsheng, AU - Guo,Xiaohua, AU - Fang,Jian, AU - Han,Jun, AU - Gu,Wenjiang, AU - Xie,Xiaoxi, AU - Sun,Zhichao, AU - Xu,Huanhai, AU - Wu,Xia, AU - Hu,Tingyang, AU - Huang,Jing, AU - Hu,Hongjie, AU - Zheng,Jiaping, AU - Luo,Jun, AU - Chen,Yutang, AU - Yu,Wenqiang, AU - Shao,Guoliang, Y1 - 2019/12/19/ PY - 2019/12/21/pubmed PY - 2019/12/21/medline PY - 2019/12/21/entrez SP - 249 EP - 271 JF - Oncology research JO - Oncol. Res. VL - 28 IS - 3 N2 - This study aimed to investigate the efficacy, safety, and prognostic factors of drug-eluting beads transarterial chemoembolization (DEB-TACE) in treating Chinese patients with liver cancer. A total of 367 liver cancer patients from 24 medical centers were consecutively enrolled in this multiple-center, prospective cohort study, including 275 hepatocellular carcinoma (HCC) cases, 37 intrahepatic cholangiocarcinoma (ICC) cases, and 55 secondary liver cancer cases. All the patients received CalliSpheres® DEB-TACE treatment. Treatment response, overall survival (OS), change of liver function, and adverse events (AEs) were assessed. DEB-TACE treatment achieved 19.9% complete response (CR) and 79.6% objective response rate (ORR), with mean OS of 384 days [95% confidence interval (CI): 375-393 days]. CR and ORR were both higher in HCC patients compared with primary ICC patients and secondary liver cancer patients, while no difference was discovered in OS. Portal vein invasion was an independent risk factor for CR, while portal vein invasion, previous conventional TACE (cTACE) treatment, and abnormal blood creatinine (BCr) were independent risk factors for ORR. In addition, largest nodule size ≥5.0 cm, abnormal albumin (ALB), and abnormal total bilirubin (TBIL) independently correlated with unfavorable OS. Most liver function indexes were recovered to baseline levels at 1-3 months after DEB-TACE. Common AEs were pain, fever, vomiting, and nausea; most of them were at mild grade. CalliSpheres® DEB-TACE is efficient and well tolerated in Chinese liver cancer patients. Portal vein invasion, previous cTACE treatment, largest nodule size, abnormal BCr, ALB, and TBIL correlate with worse prognosis independently. SN - 1555-3906 UR - https://www.unboundmedicine.com/medline/citation/31856933/The_Comprehensive_Analysis_of_Efficacy_and_Safety_of_CalliSpheres®_Drug_Eluting_Beads_Transarterial_Chemoembolization_in_367_Liver_Cancer_Patients:_A_Multiple_Center_Cohort_Study_ L2 - https://www.ingentaconnect.com/openurl?genre=article&issn=0965-0407&volume=28&issue=3&spage=249&aulast=Peng DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.